The prevalence APOE ε4 carriers ranged from 57% in the prodromal AD AT(N) group to 11% in the normal AT(N) group (with intermediate values in the SNAP and brain amyloidosis AT(N) groups). This evidence concerns the gene APOE and Alzheimer disease.